Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study to Evaluate GLPG2222 in Ivacaftor-treated Subjects With Cystic Fibrosis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03045523
Recruitment Status : Completed
First Posted : February 7, 2017
Last Update Posted : November 21, 2017
Sponsor:
Information provided by (Responsible Party):
Galapagos NV

Brief Summary:

This clinical study is a phase IIa, multi-center, randomized, double-blind, placebo-controlled, parallel group study to evaluate two doses of orally administered GLPG2222 in adult subjects with a confirmed diagnosis of CF harbouring one F508del CFTR mutation and a second gating (class III) mutation and on stable treatment with ivacaftor.

Up to 35 evaluable subjects are planned to be included in the study. Eligible subjects must be on stable treatment with physician prescribed ivacaftor (Kalydeco®) for at least 28 days at the baseline visit. They will be randomized in a 2:2:1 ratio to receive one of two active doses of GLPG2222 (150 mg q.d. or 300 mg q.d.) or placebo q.d. administered for 29 days. Subjects will be in the study for a minimum of 6 weeks and a maximum of 10 weeks, from screening until the follow-up visit.


Condition or disease Intervention/treatment Phase
Cystic Fibrosis Drug: GLPG2222 150 mg q.d. Drug: GLPG2222 300 mg q.d. Drug: Placebo Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 37 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase IIa, Randomized, Double-blind, Placebo-controlled Study to Evaluate GLPG2222 in Ivacaftor-treated Subjects With Cystic Fibrosis Harbouring One F508del CFTR Mutation and a Second Gating (Class III) Mutation
Study Start Date : January 2017
Actual Primary Completion Date : August 11, 2017
Actual Study Completion Date : August 11, 2017

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Cystic Fibrosis
Drug Information available for: Ivacaftor

Arm Intervention/treatment
Experimental: GLPG2222 Dose 1 Drug: GLPG2222 150 mg q.d.
GLPG2222 150 mg administered as a ready-to-use oral suspension, once daily (q.d.) for 29 days

Experimental: GLPG2222 Dose 2 Drug: GLPG2222 300 mg q.d.
GLPG2222 300 mg administered as a ready-to-use oral suspension, once daily (q.d.) for 29 days

Placebo Comparator: Placebo Drug: Placebo
Placebo administered as a ready-to-use oral suspension, once daily (q.d.) for 29 days




Primary Outcome Measures :
  1. Changes in adverse events [ Time Frame: at screening and at each study visit up to day 43 which is the final FU visit ]
    To evaluate the safety and tolerability of GLPG2222 as compared to placebo in terms of adverse events

  2. Changes in abnormal laboratory [ Time Frame: at screening and at each study visit up to day 43 which is the final FU visit ]
    To evaluate the safety and tolerability of GLPG2222 as compared to placebo in terms of laboratory

  3. Changes in abnormal vital signs, ECG or physical examination [ Time Frame: at screening and at each study visit up to day 43 which is the final FU visit ]
    To evaluate the safety and tolerability of GLPG2222 as compared to placebo in terms of vital signs, ECG or physical examination


Secondary Outcome Measures :
  1. Change from baseline of Sweat chloride concentration [ Time Frame: at screening and at each study visit up to day 43 which is the final FU visit ]
  2. Change from baseline of FEV1 (L) and percent predicted FEV1 for age, gender and height as assessed by spirometry [ Time Frame: at screening and at each study visit up to day 43 which is the final FU visit ]
  3. Change from baseline on the respiratory domain of Revised Cystic Fibrosis Questionnaire (CFQ-R) [ Time Frame: at screening and at each study visit up to day 43 which is the final FU visit ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 99 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Male or female subject ≥ 18 years of age, on the day of signing the Informed Consent Form (ICF).
  2. A confirmed clinical diagnosis of CF.
  3. One F508del mutation on one allele in the CFTR gene, a gating (class III) mutation (one of the following: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, or S549R) on the 2nd allele in the CFTR gene (documented in the subject's medical record or CF registry).
  4. Weight ≥ 40 kg.
  5. Stable concomitant treatment for at least 4 weeks (28 days) prior to baseline (including physician prescribed ivacaftor (Kalydeco®) 150 mg b.i.d.).
  6. Forced expiratory volume in 1 second (FEV1) ≥ 40% of predicted normal for age, gender and height at screening (pre- or postbronchodilator).

Exclusion Criteria:

  1. History of clinically meaningful unstable or uncontrolled chronic disease that makes the subject unsuitable for inclusion in the study in the opinion of the investigator.
  2. Unstable pulmonary status or respiratory tract infection (including rhinosinusitis) requiring a change in therapy within 4 weeks of baseline.
  3. Need for supplemental oxygen during the day, and >2 liters per minute (LPM) while sleeping.
  4. History of hepatic cirrhosis with portal hypertension (e.g., signs/symptoms of splenomegaly, esophageal varices, etc).
  5. Abnormal liver function test at screening; defined as aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) and/or alkaline phosphatase and/or total bilirubin (>1.5 times ULN (CTCAE Grade 2) and/or gamma-glutamyl transferase (GGT) ≥ 3x the upper limit of normal (ULN), and/or total bilirubin (>1.5 times ULN (CTCAE Grade 2).
  6. Estimated creatinine clearance < 60mL/min using the Cockroft-Gault formula at screening.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03045523


Locations
Layout table for location information
Australia
The Prince Charles Hospital
Chermside, Australia
The Alfred
Melbourne, Australia
Sir Charles Gairdner Hospital
Nedlands, Australia
Westmead Hospital
Westmead, Australia
Belgium
UZ Brussel
Brussels, Belgium
UZ Gent
Ghent, Belgium
UZ Leuven
Leuven, Belgium
Czechia
Fakultni nemocnice v Motole
Praha, Czechia
Germany
Universitaetsklinikum Carl Gustav Carus TU Dresden
Dresden, Germany
Universitätsklinikum Erlangen
Erlangen, Germany
University Children´s Hospital
Tübingen, Germany
Ireland
Cork University Hospital
Cork, Ireland
Beaumont Hospital
Dublin, Ireland
St Vincents University Hospital
Dublin, Ireland
United Kingdom
Birmingham Heartlands
Birmingham, United Kingdom
Royal Devon and Exeter
Exeter, United Kingdom
St James's University
Leeds, United Kingdom
Liverpool Heart and Chest Hospital
Liverpool, United Kingdom
Royal Brompton Hospital
London, United Kingdom
University Hospital of South Manchester
Manchester, United Kingdom
Royal Victoria Infirmary
Newcastle, United Kingdom
Southampton General Hospital
Southampton, United Kingdom
Sponsors and Collaborators
Galapagos NV
Investigators
Layout table for investigator information
Study Director: Olivier Van Steen, MD, MBA Galapagos NV

Layout table for additonal information
Responsible Party: Galapagos NV
ClinicalTrials.gov Identifier: NCT03045523     History of Changes
Other Study ID Numbers: GLPG2222-CL-201
First Posted: February 7, 2017    Key Record Dates
Last Update Posted: November 21, 2017
Last Verified: November 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Fibrosis
Cystic Fibrosis
Pathologic Processes
Pancreatic Diseases
Digestive System Diseases
Lung Diseases
Respiratory Tract Diseases
Genetic Diseases, Inborn
Infant, Newborn, Diseases
Ivacaftor
Chloride Channel Agonists
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action